JNJames Lindsay Nicklin

James Lindsay Nicklin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


James Lindsay Nicklin has a total of 528 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Is it time to drop royal patronage of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists?

    by James Nicklin, Greg Robertson

    Historically there is a strong, amiable and mutually respectful relationship between Australian and New Zealand obstetricians and gynaecologists (O&Gs) and the British O&G establishment represented by the Royal College of Obstetricians and Gynaecologists (RCOG). The ‘Royal’ prefix pays homage to this relationship. With the evolution of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG), there have been suggestions that the Royal prefix no longer accurately reflects the raison d'être and aspirations of RANZCOG. This paper will explore the arguments in favour and against dropping the Royal prefix from RANZCOG.

  • Time to stop the hand‐wringing. ‘Net zero’ hysterectomy is not an appropriate goal

    by James Nicklin

    Hysterectomy is an essential part of the treatment armamentarium for patients with malignant disease, severe prolapse, massive fibroids, with genetic mutations that predispose to endometrial cancer, and in selected patients with severe symptomatic endometriosis and adenomyosis. For patients with abnormal uterine bleeding unresponsive to non‐surgical measures, there is high‐level evidence that hysterectomy, particularly minimally invasive hysterectomy, is associated with higher rates of satisfaction and quality of life, comparable rates of serious adverse events and a lower incidence of further surgery, than endometrial resection or ablation. A ‘net zero’ hysterectomy is not an appropriate goal in contemporary gynaecological practice.


  • Open Access

    Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020

    by Andreas Obermair, Philip Beale, Clare L Scott, Victoria Beshay, Ganessan Kichenadasse, Bryony Simcock, James Nicklin, Yeh Chen Lee, Paul Cohen, Tarek Meniawy

    Obermair A, et al. J Gynecol Oncol. 2021 Oct;32(6):e95. https://doi.org/10.3802/jgo.2021.32.e95


  • Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer

    by Shih-Ern Yao, Lee Tripcony, Karen Sanday, Jessica Robertson, Lewis Perrin, Naven Chetty, Russell Land, Andrea Garrett, Andreas Obermair, Marcelo Nascimento, et al.

    Objective Interval cytoreduction following neoadjuvant chemotherapy is a well-recognized treatment alternative to primary debulking surgery in the treatment of advanced epithelial ovarian cancer where patient and/or disease factors prevent complete macroscopic disease resection to be achieved. More recently, the strain of the global COVID-19 pandemic on hospital resources has forced many units to alter the timing of interval surgery and extend the number of neoadjuvant chemotherapy cycles. In order to support this paradigm shift and provide more accurate counseling during these unprecedented times, we investigated the survival outcomes in advanced epithelial ovarian cancer patients with the intent of maximal cytoreduction following neoadjuvant chemotherapy with respect to timing of surgery and degree of cytoreduction. Methods A retrospective review of all patients aged 18 years and above with FIGO (2014) stage III/IV epithelial ovarian cancer treated with neoadjuvant chemotherapy and the intention of interval cytoreduction surgery between January 2008 and December 2017 was conducted. Overall and progression-free survival outcomes were analyzed and compared with patients who only received chemotherapy. Outcome measures were correlated with the number of neoadjuvant chemotherapy cycles and amount of residual disease following surgery. Results Six hundred and seventy-one patients (median age 67 (range 20–91) years) were included in the study with 572 patients treated with neoadjuvant chemotherapy and surgery and 99 patients with chemotherapy only. There was no difference in the proportion of patients in whom complete cytoreduction was achieved based on number of cycles of neoadjuvant chemotherapy (2–4 cycles: 67.7%, n=337/498); ≥5 cycles: 62.2%, n=46/74). Patients undergoing cytoreduction surgery after neoadjuvant chemotherapy had a median 5-year progression-free and overall survival of 24 and 38 months, respectively. No significant difference in overall survival between surgical groups was observed (interval cytoreduction: 41 months vs delayed cytoreduction: 43 months, p=0.52). Those who achieved complete cytoreduction to R0 (no macroscopic disease) had a significant median overall survival advantage compared with those with any macroscopic residual disease (R0: 49–51 months vs RConclusions Survival outcomes do not appear to be worse for patients treated with neoadjuvant chemotherapy if cytoreduction surgery is delayed beyond three cycles. In advanced epithelial ovarian cancer patients the imperative to achieve complete surgical cytoreduction remains gold standard, irrespective of surgical timing, for best survival benefit.


  • Top Cited Papers

    Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer

    by Pedro T. Ramirez, Michael Frumovitz, Rene Pareja, Aldo Lopez, Marcelo Vieira, Reitan Ribeiro, Alessandro Buda, Xiaojian Yan, Yao Shuzhong, Naven Chetty, et al.

    There are limited data from retrospective studies regarding whether survival outcomes after laparoscopic or robot-assisted radical hysterectomy (minimally invasive surgery) are equivalent to those after open abdominal radical hysterectomy (open surgery) among women with early-stage cervical cancer. In this trial involving patients with stage IA1 (lymphovascular invasion), IA2, or IB1 cervical cancer and a histologic subtype of squamous-cell carcinoma, adenocarcinoma, or adenosquamous carcinoma, we randomly assigned patients to undergo minimally invasive surgery or open surgery. The primary outcome was the rate of disease-free survival at 4.5 years, with noninferiority claimed if the lower boundary of the two-sided 95% confidence interval of the between-group difference (minimally invasive surgery minus open surgery) was greater than −7.2 percentage points (i.e., closer to zero). A total of 319 patients were assigned to minimally invasive surgery and 312 to open surgery. Of the patients who were assigned to and underwent minimally invasive surgery, 84.4% underwent laparoscopy and 15.6% robot-assisted surgery. Overall, the mean age of the patients was 46.0 years. Most patients (91.9%) had stage IB1 disease. The two groups were similar with respect to histologic subtypes, the rate of lymphovascular invasion, rates of parametrial and lymph-node involvement, tumor size, tumor grade, and the rate of use of adjuvant therapy. The rate of disease-free survival at 4.5 years was 86.0% with minimally invasive surgery and 96.5% with open surgery, a difference of −10.6 percentage points (95% confidence interval [CI], −16.4 to −4.7). Minimally invasive surgery was associated with a lower rate of disease-free survival than open surgery (3-year rate, 91.2% vs. 97.1%; hazard ratio for disease recurrence or death from cervical cancer, 3.74; 95% CI, 1.63 to 8.58), a difference that remained after adjustment for age, body-mass index, stage of disease, lymphovascular invasion, and lymph-node involvement; minimally invasive surgery was also associated with a lower rate of overall survival (3-year rate, 93.8% vs. 99.0%; hazard ratio for death from any cause, 6.00; 95% CI, 1.77 to 20.30). In this trial, minimally invasive radical hysterectomy was associated with lower rates of disease-free survival and overall survival than open abdominal radical hysterectomy among women with early-stage cervical cancer. (Funded by the University of Texas M.D. Anderson Cancer Center and Medtronic; LACC ClinicalTrials.gov number, NCT00614211.)


  • Malignant ovarian germ cell tumours in the post‐menopausal population

    by Jessica A. Robertson, Karen Sanday, James Nicklin

    Background: Malignant ovarian germ cell tumours (MOGCT) are uncommon in the general population and very rare in post‐menopausal women.Aims: To evaluate the demographics, treatment and survival of post‐menopausal women with MOGCT treated at the Queensland Centre for Gynaecological Cancer (QCGC) and compare these with pre‐menopausal women.Materials and Methods: Retrospective analysis was performed of the QCGC database from January 1981 to February 2017. The disease course of post‐menopausal women was compared with pre‐menopausal women affected by MOGCT over the same period and compared with the world literature.Results: There were six post‐menopausal women with MOGCT treated at the QCGC compared with 166 pre‐menopausal women. In the post‐menopausal group of women, there was no mortality directly attributed to germ cell ovarian disease compared with 10 (6.0%) women in the pre‐menopausal group.Conclusions: Malignant ovarian germ cell tumours are a very rare condition in post‐menopausal women. Despite some suggestion in the world literature that survival outcomes are worse in this population, this was not found in our study.


  • Open Access

    MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

    by Matthew S. Block, Robert A. Vierkant, Peter F. Rambau, Stacey J. Winham, Philipp Wagner, Nadia Traficante, Aleksandra Tołoczko, Daniel G. Tiezzi, Florin Andrei Taran, Peter Sinn, et al.


  • The future of robotic‐assisted laparoscopic gynaecologic surgery in Australia – A time and a place for everything

    by James Nicklin

    There has been a significant increase in minimally invasive surgery in gynaecology over the last 15 years, with approximately only one‐third of hysterectomies for benign disease now performed via laparotomy. While robotic surgery offers considerable technical advantages over conventional laparoscopy and is associated with only a modest learning curve, the improvement in clinical outcomes is marginal and there are several disadvantages. There are increased set‐up and operating times, the need to accommodate and maintain large sophisticated equipment, and the requirement for additional training. The preeminent issue regarding the place of robotic gynaecological surgery is cost. How this is addressed and contained will ultimately determine uptake in Australia. From the published literature to date, robotic surgery compared with conventional laparoscopic surgery is associated with marginal improvements in clinical outcomes for benign hysterectomy and endometrial cancer surgery, but little improvement for other benign gynaecological surgery or for cervical cancer surgery. Robotic surgery probably does improve clinical outcomes in obese and morbidly obese patients and is associated with improved ergonomics for the surgeon. It is likely that there will be continued substantial improvements in robotic surgical platforms into the foreseeable future and that robotic surgery will play an increasingly important role in gynaecological surgery in Australia.